Enhance and advance radiopharmaceutical discovery pipelines by providing premium, one-stop-shop R&D services and expertise.
Accelerate radiopharmaceutical speed to market, bringing life-saving diagnostics and therapies to patients.
Bring more life-saving diagnostic and therapeutic agents to patients.
Optimize the journey of drug discovery through accurate results, ensuring radiopharmaceuticals are primed for success during clinical translation.
We serve radiopharma, midsize biotech, startups and academics by leveraging our ecosystem, infrastructure and expertise to accelerate preclinical programs into clinical translation.
RPT Labworks is a Madison, WI, USA-based contract research organization (CRO) providing end-to-end preclinical radiopharmaceutical theranostics (RPT) development, optimization and testing services.
Our services range from consulting on your experimental design, radiochemistry and QC method development, conjugation and radiolabeling, radiochemistry quality control, cell handling and cell culture, in vitro assays, cancer modeling, in vivo imaging, dosimetry, efficacy and pharmacology, non-GLP radiation toxicology, ex vivo biodistribution, tissue preparation/fixation for histology, and preclinical support for IND submission.
Located in Madison, WI, USA, RPT Labworks is home to approximately 6,000 sq. ft. of state-of-the-art clean laboratory space, specifically designed to support radiochemistry, biology, imaging, and animal studies. Outfitted with high-end equipment and backed by a reliable supply of a wide range of imaging and therapeutic radionuclides, we provide everything you need under one roof.
RPT Labworks has tapped into an established personalized medicine ecosystem in Madison, WI, with strong ties to local radioisotope suppliers, radiation sciences and radiopharmaceutical theranostics companies, biotechs, and the University, where we are the beneficiaries of top talent from these entities and the UW Department of Medical Physics.
.png)
Justin Jeffery
Cofounder & CEO
Reinier Hernandez, PhD
Cofounder & CEO
Evan Sengbusch, PhD, MBA
Board Member
